Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor (vol 76, pg 89, 2013)

被引：3
|
作者：
Kubitza, D.
Roth, A.
Becka, M.
Alatrach, A.
Halabi, A.
Hinrichsen, H.
Mueck, W.
机构：
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2013年 / 76卷 / 03期
关键词：
D O I：
10.1111/bcp.12215
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：489 / 489
页数：1
相关论文
共 50 条
  • [41] Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects
    Kadokura, Takeshi
    Oikawa, Keishi
    Miyata, Koji
    Murase, Toshinobu
    Nakamura, Mashio
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2013, 2 (04): : 328 - 335
  • [42] Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects
    Kadokura, Takeshi
    Kashiwa, Makoto
    Groenendaal, Dorien
    Heeringa, Marten
    Mol, Roelof
    Verheggen, Frank
    Garcia-Hernandez, Alberto
    Onkels, Hartmut
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (08) : 431 - 441
  • [43] Abstract PIII-59: The Pharmacokinetics of YM150, an Oral Direct Factor XA Inhibitor, Exhibits Dose Proportionality with no Clinically Relevant Effect of Ethnicity or Gender (vol 89, pg s86, 2011)
    Groenendaal, D.
    Kadokura, T.
    Andersen, G.
    de Rooij, J. van de Wetering
    Heeringa, M.
    Verheggen, F.
    Heinzerling, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (03) : 468 - 468
  • [44] Effect of food on the pharmacokinetics and pharmacodynamics of R1663, an oral factor Xa inhibitor, in healthy male volunteers
    Schmitt, Christophe
    Charoin-Pannier, Anne
    McIntyre, Christine
    Zandt, Hagen
    Ciorciaro, Cornelia
    Zweigler, Lydia
    Winters, Katie
    Pepper, Tom
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (08) : 566 - 572
  • [45] EFFECT OF FAMOTIDINE ON THE PHARMACOKINETICS OF APIXABAN, AN ORAL DIRECT FACTOR Xa INHIBITOR, IN HEALTHY SUBJECTS.
    Uprett, Vijay V.
    Song, Yan
    Wang, Jessie
    Farmer, Mathew
    Pursley, Janica M.
    Li, Tong
    Frost, Charles E.
    LaCreta, Frank P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1117 - 1117
  • [46] Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects
    Kadokura, Takeshi
    Taniuchi, Yuta
    Inoue, Hiroshi
    Saito, Masako
    Iwahana, Mioko
    Yamada, Shunsuke
    Urae, Akinori
    Nakamura, Mashio
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (03) : 200 - 206
  • [47] Naproxen has no relevant effect on the safety, tolerability, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - An oral, direct factor Xa inhibitor.
    Kubitza, D
    Becka, M
    Mueck, W
    Zuehlsdorf, M
    BLOOD, 2005, 106 (11) : 532A - 533A
  • [48] Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects
    Dieterle, W
    Corynen, S
    Mann, J
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (04) : 433 - 436
  • [49] Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet-Induced Thrombin Generation and Prothrombinase Activity (vol 47, pg 1398, 2007)
    Graff, J.
    von Hentig, N.
    Misselwitz, F.
    Kubitza, D.
    Becka, M.
    Breddin, H. K.
    Harder, S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (11): : 1368 - 1368
  • [50] The pharmacokinetics and pharmacodynamics of TAK-442, an oral, direct factor Xa inhibitor following multiple dosing in healthy male subjects
    Stringer, Fran
    Scott, Graham
    Kupfer, Stuart
    Prescott, Kim
    Jenkins, Robert
    Harding, Sarah
    Cao, Charlie
    Kawamura, Masaki
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (02) : 305 - 305
12345